Drug distributor Cardinal Health to lose OptumRx contracts
Updates shares, adds analyst comment in paragraph 2 and 3
By Mariam Sunny
April 22 (Reuters) -Cardinal Health CAH.N said on Monday its contracts with UnitedHealth Group's UNH.N OptumRx, one of its largest customers, will not be renewed after they expire at the end of June, sending the drug distributor's shares down about 6%.
At least two analysts said rival McKesson MCK.N would get Optum's contracts. McKesson did not immediately respond to a Reuters request for comment.
The loss of Optum contracts was an "unexpected disappointment," Leerink Partners analyst Michael Cherny said, adding that he expects Cardinal to make up for this loss through buybacks, deals, cost cuts and new customers.
The Optum contracts, signed in 2015, contributed 16% of Cardinal's total revenue in fiscal year 2023, but the bulk of the shipments mainly comprised non-specialty medicines, Cardinal Health said.
Cardinal said it expects to partially offset the impact of losing the Optum contracts through customer additions and growth in its more profitable specialty pharmacy business.
It is banking on strong sales of high-priced specialty medicines that treat diseases including cancer and rheumatoid arthritis, at a time when its medical devices distribution unit struggles with rising transportation and labor costs as well as supply constraints.
The Ohio-based drug distributor said it anticipates lower adjusted free cash flow in fiscal 2025 due to loss of the contracts and reiterated its fiscal 2024 adjusted profit forecast.
EvercoreISI analyst Elizabeth Anderson estimates the loss of Optum contracts to impact Cardinal's 2025 profit by 45-50 cents.
Cardinal has, however, not yet provided guidance for its fiscal 2025, which ends in June 2025.
Cardinal declined to provide any further comment on the OptumRx contracts, and UnitedHealth did not respond to Reuters request for comment.
OptumRx is a pharmacy benefit manager which acts as an intermediary between insurers and drugmakers to negotiate the prices of prescription drugs.
Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Shinjini Ganguli
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
